Given the unavailability of clinically approved CD73 inhibitors for cancer, drug repurposing, which is intended to find new uses for clinically approved drugs [131], may hold promise as an alternative and cost-effective way of targeting the CD73-adenosinergic signaling pathway. The gene discussed is NT5E; the disease is cancer.